Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Radiation Oncology
Published in: Journal of Radiation Oncology 3/2019

01-09-2019 | Prostate Cancer | Original Research

Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy

Authors: Brandon M. Lehrich, John Ravera, Navid Mostaghni, Jeffrey Yoshida, Robert Torrey, Ruben Baghdassarian, Michael Gazzaniga, Alan Weinberg, Cu Phan, Stuart Chalfin, Lucy Barnes, Albert Mesa, Kenneth Tokita

Published in: Journal of Radiation Oncology | Issue 3/2019

Login to get access

Abstract

Purpose

We report on the long-term clinical outcomes of clinically localized prostate carcinoma (PCa) patients treated with external beam radiotherapy (EBRT) in combination with high-dose-rate brachytherapy boost (HDR-B).

Material and methods

Between 2002 and 2015, 538 prostate carcinoma patients underwent combined HDR-B (Ir-192) of 16 Gy over 4 fractions and EBRT of 59.4 Gy over 33 fractions. Patients were segregated into risk groups according to the NCCN guidelines. The Cox proportional hazards model was used to elicit risk factors for decreased biochemical relapse-free survival (bRFS), distant metastasis-free survival (dMFS), and overall survival (OS). Patients were graded by a board of radiation oncologists for gastrointestinal (GI) and genitourinary (GU) adverse events due to radiation using CTCAE v4.03 guidelines at follow-up.

Results

The mean follow-up was 49 months (range 6–145 months). Five-year bRFS for low-, intermediate-, and high-risk patients were 96.7%, 93.0%, and 78.5%, respectively. Five-year dMFS for low-, intermediate-, and high-risk patients were 100%, 96.4%, and 80.7%, respectively. Five-year OS rates for low-, intermediate-, and high-risk patients were 98.6%, 97.5%, and 94.7%, respectively. Five-year incidence of late grade 2 and 3 GI toxicities were 6.3% and 0.7%, respectively, and the five-year incidence of late grade 2 and 3 GU toxicities were 11.7% and 1.3%, respectively. Multivariate analysis revealed a higher Gleason score, initial pre-treatment PSA, and no hormonal therapy use as predictive for decreased biochemical control.

Conclusion

Combined HDR-B/EBRT for the treatment of clinically localized prostate cancer provides superb clinical outcomes with excellent 5-year bRFS, dMFS, OS, and late GI/GU toxicity rates.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
2.
Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternbya NH, Tulinius H (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20(5):680–688PubMedCrossRef
3.
Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176(4 Pt 1):1415–1419PubMedCrossRef
4.
Zelefsky MJ et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876–881PubMedCrossRef
5.
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294(10):1233–1239PubMedCrossRef
6.
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 28(7):1106–1111PubMedPubMedCentralCrossRef
7.
Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139PubMedCrossRef
8.
Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE (2013) Radiation therapy modalities in prostate cancer. J Natl Compr Cancer Netw 11(4):414–421CrossRef
9.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMedCrossRef
10.
Spratt DE et al (2014) Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 114(3):360–367PubMed
11.
Bowes D, Crook J (2011) A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature. Curr Opin Urol 21(3):219–224PubMedCrossRef
12.
Fowler FJ Jr et al (2000) Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283(24):3217–3222PubMedCrossRef
13.
Cooperberg MR, Carroll PR (2015) Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314(1):80–82PubMedCrossRef
14.
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445PubMedPubMedCentralCrossRef
15.
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE, ProtecT Study Group* (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437PubMedPubMedCentralCrossRef
16.
Huang GJ, Sadetsky N, Penson DF (2010) Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 183(6):2206–2212PubMedPubMedCentralCrossRef
17.
Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, Lukka HR, Levine M (2005) Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23(6):1192–1199PubMedCrossRef
18.
Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P (2007) High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 84(2):114–120PubMedCrossRef
19.
Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103(2):217–222PubMedCrossRef
20.
Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H (2010) Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 78(3):751–758PubMedPubMedCentralCrossRef
21.
Morris WJ et al (2017) Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285PubMedCrossRef
22.
Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N (2017) ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):286–295PubMedCrossRef
23.
Kee DLC, Gal J, Falk AT, Schiappa R, Chand ME, Gautier M, Doyen J, Hannoun-levi JM (2018) Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials. Cancer Treat Rev 70:265–271PubMedCrossRef
24.
Yeh J, Lehrich B, Mesa A, Tran C, Barnes L, Long C, Yoshida J, Torrey R, Gazzaniga M, Albert S, Weinberg A, Alavi A, Baghdassarian R, Chalfin S, Ravera J, Tokita K (2017) Three-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy. Transl Cancer Res 6(2):269–274CrossRef
25.
Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M III, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA (2016) Prostate Cancer, version 1.2016. J Natl Compr Cancer Netw 14(1):19–30CrossRef
26.
Yeh J, Lehrich B, Tran C, Mesa A, Baghdassarian R, Yoshida J, Torrey R, Gazzaniga M, Weinberg A, Chalfin S, Ravera J, Tokita K (2016) Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 15(3):283–287PubMedCrossRef
27.
Roberts, T. and M. Roach, 3rd, The evolving role of pelvic radiation therapy. Semin Radiat Oncol, 2003. 13(2): p. 109–120
28.
29.
Roach M 3rd et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974PubMedCrossRef
30.
Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53(5):1111–1116PubMedCrossRef
31.
Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317PubMedCrossRef
32.
Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23):3904–3911PubMedCrossRef
33.
Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028–1033PubMedCrossRef
34.
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74PubMedCrossRef
35.
Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD, Stephens RJ, Syndikus I, Parmar MK, RT01 collaborators (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487PubMedCrossRef
36.
Al-Mamgani A et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988PubMedCrossRef
37.
Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74(5):1405–1418PubMedCrossRef
38.
39.
Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA (2000) Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 55(1):85–90PubMedCrossRef
40.
Dayes IS, Parpia S, Gilbert J, Julian JA, Davis IR, Levine MN, Sathya J (2017) Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Int J Radiat Oncol Biol Phys 99(1):90–93PubMedCrossRef
41.
Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31):3860–3868PubMedPubMedCentralCrossRef
42.
Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, Pinzi V, Arcangeli G (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178PubMedCrossRef
43.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O’Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E, CHHiP Investigators (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060PubMedPubMedCentralCrossRef
44.
Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048–1055PubMedCrossRef
45.
Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306–1316PubMedCrossRef
46.
Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen G’N, Zaider M, Zelefsky MJ (2013) Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 12(1):44–49PubMedCrossRef
47.
Martinez-Monge R et al (2012) External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 82(3):e469–e476PubMedCrossRef
48.
Neviani CB, Miziara MA, de Andrade Carvalho H (2011) Results of high dose-rate brachytherapy boost before 2D or 3D external beam irradiation for prostate cancer. Radiother Oncol 98(2):169–174PubMedCrossRef
49.
Phan TP, Syed AMN, Puthawala A, Sharma A, Khan F (2007) High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 177(1):123–127; discussion 127PubMedCrossRef
50.
Eulau SM et al (2000) High dose rate 192Iridium brachytherapy in localized prostate cancer: results and toxicity with maximum follow-up of 10 years. Int J Radiat Oncol Biol Phys 48(3):149CrossRef
51.
Yaxley JW, Lah K, Yaxley JP, Gardiner RA, Samaratunga H, MacKean J (2017) Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years. BJU Int 120(1):56–60PubMedCrossRef
52.
Khor R, Duchesne G, Tai KH, Foroudi F, Chander S, van Dyk S, Garth M, Williams S (2013) Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 85(3):679–685PubMedCrossRef
53.
Spratt DE et al (2017) American Brachytherapy Society Task Group Report: combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 16(1):1–12PubMedCrossRef
54.
Stock RG, Yamalachi S, Hall SJ, Stone NN (2010) Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. J Urol 183(2):546–550PubMedCrossRef
55.
Bittner N, Merrick GS, Galbreath RW, Butler WM, Adamovich E (2015) Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories. Brachytherapy 14(6):766–772PubMedCrossRef
56.
Ghadjar P, Thalmann GN (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 110(10):E431–E432 author reply E432PubMedCrossRef
57.
Singhal S, Jamaluddin MF, Lee E, Sloboda RS, Parliament M, Usmani N (2017) Clinical factors and dosimetry associated with the development of prostate brachytherapy-related urethral strictures: a matched case-control study. Brachytherapy 16(4):797–805PubMedCrossRef
58.
Sullivan L, Williams SG, Tai KH, Foroudi F, Cleeve L, Duchesne GM (2009) Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 91(2):232–236PubMedCrossRef
59.
King CR (2002) LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models. Brachytherapy 1(4):219–226PubMedCrossRef
60.
King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D’Amico AV, Nguyen PL, Orio PF III (2019) A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy 18:186–191PubMedCrossRef
Metadata
Title
Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy
Authors
Brandon M. Lehrich
John Ravera
Navid Mostaghni
Jeffrey Yoshida
Robert Torrey
Ruben Baghdassarian
Michael Gazzaniga
Alan Weinberg
Cu Phan
Stuart Chalfin
Lucy Barnes
Albert Mesa
Kenneth Tokita
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 3/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00401-2

Other articles of this Issue 3/2019

Journal of Radiation Oncology 3/2019 Go to the issue

Original Research

Impact of choice of dose calculation algorithm on PTV and OAR doses in lung SBRT

Original Research

Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes

Original Research

Patterns of relapse in older women diagnosed with estrogen receptor (ER)–positive early-stage breast cancer (BC) treated with lumpectomy without adjuvant endocrine therapy (ET)

Original Research

Evaluating improvements in cardiac dosimetry in breast radiotherapy and comparison of cardiac sparing techniques

Original Research

Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer

Letter to the Editor

Letter to the Editor concerning “Re-irradiation in gynaecological cancers, present experiences and future hopes”
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits